October 17, 2017 09:04 AM EDT
Discovery

Take­da is beef­ing up its NASH pipeline with a $470M dis­cov­ery deal with He­mo­S­hear

Arsalan Arif

Founder

Ten months af­ter ty­ing up with Arc­turus on an RNA pro­gram for NASH, Take­da is back beef­ing up its pipeline for the liv­er dis­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

A look at biotech's year of the megaround

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Re­gen­eron buys Lon­don-based oc­u­lar biotech

GSK’s Nu­cala bags an­oth­er Chi­na ap­proval, but biggest test yet to come

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times